Five days' incubation with acyclic retinoid effected a dose-dependent induction of differentiation.

A clinical trial of acyclic retinoid for the differentiation induction therapy of APL may be worthwhile.

In contrast, acyclic retinoid is reported to have a much wider safety margin than that of ATRA.